MAPK6
MOLECULAR TARGETmitogen-activated protein kinase 6
MAPK6 (mitogen-activated protein kinase 6) is targeted by 10 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting MAPK6
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | gefitinib | 5.67 | 290 |
| 2 | vandetanib | 4.30 | 73 |
| 3 | canertinib | 3.53 | 33 |
| 4 | bms 387032 | 3.47 | 31 |
| 5 | fedratinib | 3.40 | 29 |
| 6 | jnj 7706621 | 3.09 | 21 |
| 7 | bms 345541 | 2.71 | 14 |
| 8 | kw 2449 | 2.64 | 13 |
| 9 | ravoxertinib | 2.08 | 7 |
| 10 | Crizotinib | 0.69 | 1 |
About MAPK6 as a Drug Target
MAPK6 (mitogen-activated protein kinase 6) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 10 compounds with documented MAPK6 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
MAPK6 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.